marked.bio

HER2 ADC · ADC

trastuzumab emtansine

3 active trials across 6 of our biomarkers, targeting HER2. Not approved for any biomarker on marked.bio yet.

Also known as T-DM1, Kadcyla.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
HER2 (ERBB2) activating mutation 2 3 Phase 2
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 1 2 Phase 2
ALK fusion 0 1 –
BRAF V600E 0 1 –
EGFR exon 19 deletion / L858R 0 1 –
RET fusion or mutation 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of trastuzumab emtansine.

  1. Enliven Therapeutics 1

Trials

3 of 7 trials shown

  1. Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

    Recruiting Phase 2 NRG Oncology Started 2023Primary completion 2028-07 NCT05408845

    docetaxeltrastuzumabtrastuzumab deruxtecan FDA EUtrastuzumab emtansine

    Pathologically (histologically or cytologically) proven diagnosis of HER2-positive OR HER2-low expressing recurrent/metastatic salivary gland cancer (SGC)

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8

  2. Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas

    Recruiting Phase 2 Dana-Farber Cancer Institute Started 2020Primary completion 2028-02 NCT04620187

    trastuzumabtrastuzumab emtansine

    HER2 or ERBB2 mutated on tumor genomic sequencing assay (see Section 9.1 for permitted HER2 mutations)

    HER2 (ERBB2) activating mutationSalivary Gland Cancer, HER2 Gene Mutation

  3. ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer

    Active, not recruiting Phase 1 Enliven Therapeutics Started 2023Primary completion 2026-07 NCT05650879

    ELVN-002trastuzumab deruxtecan FDA EUtrastuzumab emtansine

    HER2 mutation identified by tissue (fresh or archival) or ctDNA.

    HER2 (ERBB2) activating mutationHER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification